reason report
bottom line friday astrazeneca azn op announc
phase adaura trial tagrisso adjuv egfr-mut non-
small lung cancer nsclc stop earli due overwhelm
efficaci preplan interim analysi success set like
establish drug approv adjuv target option
egfr patient believ may difficult checkpoint
inhibitor establish similar efficaci given low tumor burden prime
immun system follow surgic excis importantli besid
fundament valu adjuv set forecast
peak success phase adaura trial valid
tagrisso activ earlier line nsclc treatment key driver
drug growth follow posit interim analysi
updat model increas tagrisso peak penetr adjuv
egfr-mut nsclc prior estim
tagrisso peak revenu prior us
world-wide separ fda announc
approv azn/mrk op koselugo selumetinib pediatr
symptomat pn partner daiichi sankyo indic
quarter launch sale enhertu would higher
anticip updat model reflect increment
tagrisso revenu de-risk selumetinib strong enhertu
launch result pt
tagrisso succe interim analysi adjuv nsclc
set phase adaura trial double-blind placebo-
control trial tagrisso adjuv set patient stage
ib ii iiia egfr-mut nsclc primari endpoint disease-
free surviv overal surviv key secondari endpoint base
overwhelm efficaci interim analysi independ
data monitor committe idmc trial unblind earlier
origin anticip continu assess overal surviv
azn indic data present futur medic meet
regulatori submiss underway believ posit
interim data valid tagrisso opportun earlier line therapi
beyond metastat set think also bode well
phase laura trial evalu monotherapi follow
chemoradi patient stage unresect egfr-mut
dcf discount
termin growth rate
net debt total capit
price-to-earnings lt ep growth
year price history/av daili volume mil azn
compani inform svb leerink llc research
revenu ep per adr share
pleas refer page import disclosur price chart analyst certif
azn/mrk koselugo selumetinib approv
symptomat pn koselugo selumetinib mek inhibitor
part azn mrk strateg oncolog collabor
also includ lynparza approv koselugo pediatr
patient neurofibromatosi type symptomat plexiform
neurofibroma nf line anticip pdufa date
label data larg reflect phase sprint trial data present
koselugo show overal respons rate
patient respons durabl patient achiev
durat respons dor month koselugo label
also includ sever warn precaut highlight risk
cardiomyopathi ocular toxic gastrointestin toxic skin toxic
increas creatinin phosphokinas larg consist
data last shown forecast peak sale koselugo
world-wide remind azn book revenu
royalti paid rate half gross profit merck
pursuant term collabor
updat model pt follow tagrisso news
updat model increas tagrisso penetr adjuv
nsclc set approv target option
egfr patient increas penetr result tagrisso us
peak revenu prior us
world-wide follow koselugo approv
increas probabl success po us
also increas enhertu us revenu base
daiichi sankyo recent guidanc suggest sale
model chang result new pt broadli
also updat estim total product sale
prior mainli driven faster anticip china
recoveri pandem base compani guidanc
also updat extern revenu
prior oper incom prior
multipl divest occur
rate astrazeneca azn outperform pt astrazeneca global
biopharmaceut compani success transit compani focus
primarili therapeut treat gener medic condit one driven
oncolog portfolio expect grow compound annual growth rate
forecast report oncolog revenu exceed total revenu
compani proport driven best-in-class/market leader asset
tagrisso lynparza imfinzi calquenc enhertu view astrazeneca
portfolio unparallel larg pharmaceut univers term innov
anticip growth mani asset develop intern compani
also engag extern acquisit bolster pipelin well strateg
collabor deem prudent compani also invest
infrastructur geograph area high growth like china still demand
legaci asset well new product anticip annual growth
astrazeneca focu oncolog drug like streamlin compani expens
translat bottom line improv margin ep
valu astrazeneca azn per base result discount cash
flow dcf analysi contempl free cash flow forecast
assum termin growth rate weight averag cost capit wacc
azn dcf oper less increas work less capit pv pv termin enterpris less dilut equiti valu astrazeneca plc
 clinic trial risk astrazeneca numer late-stag clinic asset well sever
approv product meaning label expans opportun depend success
clinic trial includ imfinzi lynparza calquenc enhertu clinic trial failur late-
stage clinic asset repres risk current price target
 regulatori risk even posit clinic trial result market author requir
approv regul variou jurisdict regulatori delay reject
applic key pipelin product would repres risk current valuat
 competit risk astrazeneca market product competit therapeut area includ
oncolog renal/cardiovascular respiratori competit could lead azn product
sale materi estim repres risk current price target
 price reimburs legisl affect drug price includ propos legisl
 could link drug price intern benchmark risk commerci
companyprogram/drugtherapeut areaeventtimingev typetri phaseastrazenecaimfinzihead neck cancerphas kestrel data imfinzi/ imfinzi treme/ soc head neck trial gastric cancerphas data enhertu gastric cancer potenti trial nsclcphase data enhertu mutat nsclc potenti trial phase data enhertu potenti trial breast /bladderphas combin data enhertu opdivo breast/bladd cancer potenti trial dataphiazn/mrklynparzaovarian cancerpotenti approv lynparza broad ovarian cancer mainten cancerpotenti approv lynparza hrr mcrpc himalaya imfinzi/imfinzi treme/sorafenib trial dataphiiiastrazenecaimfinzinsclcphas aegean imfinzi chemo data neoadjuv stage resect nsclc trial dataphiiiastrazenecaimfinzinsclcphas imfinzi chemort vs placebo chemort data unresect locally-advanc trial denali mild moder trial dataphiiiastrazenecafasenraasthmaphas meltemi ponent trial asthmat adult ic plu agonist trial dataphiiiastrazenecafasenranas polyposisdata phase ostro sever bilater nasal trial dataphiiiastrazenecatezepelumabasthmadata phase navig trial sever trial dataphiiiazn/fgenroxadustatckd anemia potenti us approv roxadustat treatmet anemia submiss phiii poseidon trial nsclc imfinzi chemo vs imfinzi treme chemo vs chemo surviv data phase poseidon trial trial dataphiiiastrazenecaimfinzinsclcpotenti regulatori submission/accept poseidon trial near-term astrazeneca catalyst astrazeneca plc
astrazeneca mn except ep
sale
net loss attribut non-controlling interest
net incom loss attribut azn
svb leerink estim compani file
